View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
November 11, 2021

Enlivex obtains approval for Covid-19 therapy trial expansion to Spain

Phase IIb trail will assess the efficacy and safety of Allocetra when given in addition to the standard of care therapy.

Enlivex Therapeutics has received authorisation from the Spanish Agency of Medicines and Medical Devices (AEMPS) to expand its Phase IIb clinical trial of cell therapy Allocetra in Covid-19 patients to sites in the country.

The multi-centre, placebo-controlled, blinded, randomised clinical trial will assess the universal, off-the-shelf therapy to treat severe and critical patients with Covid-19 who have acute respiratory distress syndrome (ARDS).

Many diseases such as sepsis, Covid-19 and solid cancers reprogramme macrophages out of their homeostatic state and significantly contribute to the disease severity.

Allocetra is being developed to restore macrophage homeostasis and offer a new immunotherapeutic mechanism of action for life-threatening diseases that are defined as ‘unmet medical needs’.

It can be used as a standalone treatment or along with other therapeutic agents.

In this Phase IIb trial, the efficacy and safety of the cell therapy will be investigated when given in addition to standard of care therapy.

It is currently enrolling subjects at clinical sites in Israel and is anticipated to recruit up to 152 patients.

Survival without ventilation and recovery for each of the severe and critical subject sub-populations are the two primary goals of the trial.

Enlivex CEO Oren Hershkovitz said: “We believe AEMPS’ decision to authorise this expansion, together with their prior decision authorising the expansion of our sepsis trial, speaks to Allocetra’s broadly applicable mechanism of action, the strength of our clinical datasets, and the rigour of our study designs and manufacturing process.

“The inclusion of several European countries in our ongoing clinical trials is an important component of our regulatory strategy, and one that we plan to continue executing by working with regulatory agencies in additional countries.”

The company stated that the Phase IIb trial is supported by the previously reported positive data obtained from Phase Ib and Phase II investigator-initiated trials of the therapy in severe and critical Covid-19 patients.

The total data from the trials showed that the off-the-shelf cell therapy was safe and well-tolerated, and no deaths were reported on day 28 of the follow-up period.

Additionally, 90.5% of subjects recovered from their condition and were discharged from the hospital after an average of 5.6 days after taking Allocetra.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU